Skip to content

Somapharm News

Investor event

On November 25, 2019, our very successful first event for investors and interested parties took place. The response of the attendees, from private persons to

More information

BioTempero

With the successful proof of principle tests at the University Hospital in Tübingen, we have taken the next step towards licensing BioTempero and are thus

More information

Management

The management of Somapharm AG is proud and pleased about the completion and dispatch of the new share certificates for our shareholders. Since the parliamentary

More information

CARDISIO

The fast and precise screening method for early detection of heart disease and prevention of a surprising heart attack. Complementing ALiSE, we are launching Cardisio,

More information

Website

After refreshing our public appearance we are pleased to present our new website (www.somapharm.ch). Our website appears in a new design and offers extensive information

More information

ALiSE

The management of Somapharm AG is very pleased to have been granted exclusive distribution rights in Europe, including Switzerland, for a new portable and miniaturized

More information

BARS

In cooperation with the company FISO Technologies Inc. from Canada, and supported by Innoswiss, a new sensor for intensive care measurement purposes is currently being

More information

The move

At the beginning of May, the long-planned relocation of Somapharm AG was realized. The headquarters will remain unchanged at Ruessenstrasse 5a in Baar. Due to

More information

Development discussions

Development discussions are currently taking place in the field of urodynamic flow measurements and urine volume collection in intensive care units. This should enable the

More information

The measurement catheter

The documents for the clinical tests were submitted to the Ethics Committee of the University Hospital in Tübingen towards the end of March. The approval

More information